Huiai Zeng

机构：Henan Cancer Hospital

发表论文 49 篇 · 总被引 141 次 · h-index 8

代表论文

• Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial (2023 · Nature Communications · 被引 14)
• Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial (2024 · EClinicalMedicine · 被引 11)
• Utidelone Plus Bevacizumab for ERBB2 -Negative Metastatic Breast Cancer and Active Brain Metastases (2025 · JAMA Oncology · 被引 5)
• Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases. (2024 · Journal of Clinical Oncology · 被引 5)
• Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial. (2023 · Journal of Clinical Oncology · 被引 3)
• HER2-ADC trastuzumab rezetecan (SHR-A1811) in HER2-positive breast cancer with brain metastases: Update results from REIN trial. (2025 · Journal of Clinical Oncology · 被引 2)